Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 442Stomach Neoplasms 290Rectal Neoplasms 266Colonic Neoplasms 191Pancreatic Neoplasms 175Neoplasm Metastasis 110Esophageal Neoplasms 87Neoplasms 68Carcinoma, Hepatocellular 59Adenocarcinoma Of Esophagus 47Adenocarcinoma 46Lymphoma, Large B-Cell, Diffuse 44Cholangiocarcinoma 44Carcinoma, Non-Small-Cell Lung 41Biliary Tract Neoplasms 37Gallbladder Neoplasms 30Gastrointestinal Neoplasms 29Recurrence 25Liver Neoplasms 24Ovarian Neoplasms 23Esophageal Squamous Cell Carcinoma 23Breast Neoplasms 22Peritoneal Neoplasms 17Bile Duct Neoplasms 17Unspecified Adult Solid Tumor, Protocol Specific 16Parkinson Disease 4, Autosomal Dominant Lewy Body 14Locally Advanced Rectal Cancer 13Head and Neck Neoplasms 13Lung Neoplasms 12Lymphoma, Non-Hodgkin 11

Interventions

Gemcitabine 4Leucovorin 2Fluorouracil 2tremelimumab 1pamrevlumab 1irinotecan sucrosofate 1folfirinox 1durvalumab 1Taxes 1Radiosurgery 1Oxaliplatin 1Medical Marijuana 1Irinotecan 1Heavy Ion Radiotherapy 1Chemoradiotherapy 1Capecitabine 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Pancreatic Cancer Non-resectable × Oxaliplatin × Clear all
NCT05047991 2021-09-17

Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

CSPC Ouyi Pharmaceutical Co., Ltd.

Phase 2 Unknown
153 enrolled
Gastrointestinal

Pancreatic Cancer Non-resectable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡